



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/889,845	07/23/2001	Shozo Shoji	MIT-C102	1190
30132 7590 12/14/2004 GEORGE A. LOUD 3137 MOUNT VERNON AVENUE			EXAM	INER
			PARKIN, JEFFREY S	
ALEXANDRIA			ART UNIT	PAPER NUMBER
			1648	
			DATE MAILED: 12/14/2004	,

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/889,845	SHOJI, SHOZO
Notice of Abandonment	Examiner	Art Unit
	Jeffrey S. Parkin, Ph.D.	1648
The MAILING DATE of this communication ap		
This application is abandoned in view of:		
Applicant's failure to timely file a proper reply to the Offic (a) ☐ A reply was received on (with a Certificate of period for reply (including a total extension of time of	Mailing or Transmission dated month(s)) which expired on), which is after the expiration of the
(b) A proposed reply was received on, but it does		· ·
(A proper reply under 37 CFR 1.113 to a final rejection application in condition for allowance; (2) a timely file Continued Examination (RCE) in compliance with 37	d Notice of Appeal (with appeal fee)	
(c) ☐ A reply was received on but it does not constite final rejection. See 37 CFR 1.85(a) and 1.111. (See		ttempt at a proper reply, to the non-
(d) ☐ No reply has been received.		
 Applicant's failure to timely pay the required issue fee an from the mailing date of the Notice of Allowance (PTOL-4) (a) The issue fee and publication fee, if applicable, wa), which is after the expiration of the statutory particle. 	85). s received on (with a Certifi	icate of Mailing or Transmission dated
(b) ☐ The submitted fee of \$ is insufficient. A balance	e of \$ is due.	
The issue fee required by 37 CFR 1.18 is \$	· · · · · · · · · · · · · · · · · · ·	7 CFR 1.18(d), is \$
(c) The issue fee and publication fee, if applicable, has n		
3. Applicant's failure to timely file corrected drawings as req Allowability (PTO-37).	uired by, and within the three-month	n period set in, the Notice of
 (a) ☐ Proposed corrected drawings were received on after the expiration of the period for reply. 	_ (with a Certificate of Mailing or Tra	ansmission dated), which is
(b) \square No corrected drawings have been received.		
4. The letter of express abandonment which is signed by the applicants.	e attorney or agent of record, the as	ssignee of the entire interest, or all of
5. The letter of express abandonment which is signed by an 1.34(a)) upon the filing of a continuing application.	n attorney or agent (acting in a repre	esentative capacity under 37 CFR
6. The decision by the Board of Patent Appeals and Interfer of the decision has expired and there are no allowed claim		use the period for seeking court review
7. Mathematical The reason(s) below:		
Applicants' reply filed 02 March, 2004, does not cor the communication mailed 13 February, 2004. Appl said communication. Since the deficiencies were no expired, the application is abandoned.	icants' reply failed to correct the	deficiencies clearly set forth in
Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdra	aw the holding of abandonment under 37	Art Unit: 1648



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark, Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alcrandria, Virginia 22313-1450 www.usqio.gsw

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/889,845	07/23/2001	Shozo Shoji	MIT-C102	1190	
30132 75	90 02/13/2004		EXAM	INER	
GEORGE A. LOUD 3137 MOUNT VERNON AVENUE			PARKIN, JI	PARKIN, JEFFREY S	
ALEXANDRIA			ART UNIT	PAPER NUMBER	
			1648		
			DATE MAILED: 02/13/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET N
989845			
		EXAMINER	
		ART UNIT	PAPER NUMBER
		DATE MAIL	FD-

Please find below a communication from the EXAMINER in charge of this application Commissioner of Patents

The communication filed on 03 November, 2003, is not fully responsive to the last Office action for the reason(s) set forth on the attached Notice to Comply with the Sequence Rules or CRF Diskette Problem Report. Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 C.F.R. § 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached CRF Diskette Problem Report with the reply.

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 8:30 AM to 6:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisors, Laurie Scheiner or James Housel, can be reached at (571) 272-0910 or (571) 272-0902, respectively.

Respectfully,

Jeffrey S. Parkin, Ph.D.

Art/Unit 1648

09 February, 2004

09/889,845

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not
comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the
following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR
the distribution of the di

<u>Z</u>	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
X	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7.	Other:

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RECEIVED



"NOV 1 0 2003

TECH CENTER 1600/2900

RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	09/889.845
Source:	1600
Date Processed by STIC:	11/6/03

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or.
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 703-308-4212; FAX: 703-308-4221

Effective 12/13/03: TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkr41note.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry directly to (EFFECTIVE 12/01/03):
 U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
- Federal Express, United Parcel Service, on other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1903-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 10/08/03

delete

Decienemeneuese, r,d,p,t,d,m,b,d ,k,h,r,s,h,m,f

•	<110> Nissui Pharmaceutical Co., Ltd.	spessiff Comply
٠.	<120> Cyclo dodecapeptide and aids vaccine Conte	acted Distrette Needer June
•	-130s Navoo3433aa	221 -4 -
•	<160> 3 1 ENT Oppt	ide is in whiceingt source
,•	<150> NSM003422FCT <160> 3 <210> 1 <211> 12 Offlein Alus on (2237 line: FJI: pept)	The second second
		· · · · · · · · · · · · · · · · · · ·
	(212) PRT	Atto Needer mater
	<213> Artificial sequence con used a response	a leaded
• '	(300)	207. It is a header"
	<301> Shozo Shoji	- 2
	302> Synthesis of Cyclo-oligo peptide and its biological ai) do you only
	ctivity)?	7.45 goa
`	303> Japan Pharmacology Academy Kyushu branch Mass meeting	Mean
	Lecture summary collection	
	<306> 43	"activity"!
n Ato	<307> 1998-11-10 24007 I	<i>y</i> .
يستعلول	Arg Asp Asp Ala Glu Gly Glu Lys Gln Ser Asp Gly	O 1
		. 120
	(210> 2 211> 5 delete These invalid mark	rere lesse.
	<212> PRT	losure aneso
	<213>Artificial Sequence Peplan	John Marie
	<220> paptide /40072 on <2251 XXX	acid number
مے معلول (-400> Glu Ala Asp Asp Arg	are aligned properly
000	5	
	<210> 3 <211> 5	Po hot use TAB
	<211> 5 <212> PRT egolain on (2237 line	10 101 1002 1110
	(212) Autificial Company	100,000
	(220) pentide	codes between
منا	Aftificial sequence (220) peptide (2400) Ser Gln Lys Glu Gly (5)	aners seed runtere
, ofter	5	anero or
ستولا		

1) Corsult Sequence Ruler for VALID format. 2) see tem 11 on Error Summary Sheet.